Important Risk Minimisation Information for Healthcare Professionals.
This video shows the complete steps required for the correct preparation and administration of Eligard® (leuprorelin acetate). The video can be watched in full or viewed as individual chapters. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks. It is recommended that healthcare professionals who prepare/administer Eligard® review these instructions on a regular basis to ensure they always follow the correct steps.
Important information
Eligard® should only be prepared, reconstituted and administered by a healthcare professional who is familiar with the proper procedures.
If the product is not prepared appropriately, it should not be administered as lack of clinical efficacy may occur due to incorrect reconstitution of the product.
All cases of incorrect storage, preparation, reconstitution and administration of Eligard® or any other adverse reaction should be reported to Recordati Ireland Ltd. Tel.: 021 437 9400. email: medinfo@recordati.co.uk or to HPRA Pharmacovigilance, Website: www.hpra.ie
Continue To Video
Please refer to www.medicines.ie or to the HPRA website: www.hpra.ie to access the current version of the SmPC.
All cases of incorrect storage, preparation, reconstitution and administration of Eligard® or any other adverse reaction should be reported to Recordati Ireland Ltd. Tel.: 021 437 9400. email: medinfo@recordati.co.uk or to HPRA Pharmacovigilance, Website: www.hpra.ie
RIL-ELI-23-001
DOP: July 2023
All cases of incorrect storage, preparation, reconstitution, and administration of Eligard® or any other adverse reactions should be reported to Recordati Ireland Ltd. Tel.: 021 437 9400. email: medinfo@recordati.co.uk , or to HPRA Pharmacovigilance, Website: www.hpra.ie
Information contained seeks to reinforce the safe and effective conditions of use of Eligard® according to the approved Summary of Product Characteristics.
The tool does not generate data or read-out that can be considered as of clinical predictive value or inform dosing adjustments or therapeutic monitoring.
Information provided in this tool is a reminder on how to use Eligard® safely and effectively. The HCPs should refer to the approved SmPC for guidance.
Malfunction of the software would unlikely impact on patient care because the dosing is individually determined following the prescribing physician’s clinical assessment of the patient under his care. Nor does it seek to replace the health professional’s skills to prepare and administer the treatment according to the approved Summary of Product Characteristics.
Lek Eligard je zamenjen sa lekom Eligard sa sistemom spojenih špriceva.
Molimo izaberite lek koji VI imate, birajući jednu od donjih opcija.
ELI_2019_0003_AB
Datum pripreme: Decembar 2024.
This tool is intended for healthcare professionals responsible for administering Eligard®.
For further information, ask your doctor
Important Risk Minimisation Information for Healthcare Professionals.
This video shows the complete steps required for the correct preparation and administration of Eligard® (leuprorelin acetate). The video can be watched in full or viewed as individual chapters. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks. It is recommended that healthcare professionals who prepare/administer Eligard® review these instructions on a regular basis to ensure they always follow the correct steps.
Are you a healthcare professional?
This tool has been funded and developed by Recordati S.p.A.
RIL-ELI-23-001
DOP: July 2023